Coronavirus disease 2019 complications in patients with hidradenitis suppurativa: A multicenter analysis

Raiker, Rahul; Pakhchanian, Haig; Pham, James P; Phan, Kevin

doi:10.1111/1346-8138.16073

Cited by 5 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings may be due to the more consistent medical care of HS patients in the UAMS system being evaluated for their HS compared to HS−/COVID+ patients presenting for acute care leading to hospitalization. These findings are in line with previous studies demonstrating that HS patients did not have worse COVID-19 outcomes compared to the general population [ 4 , 5 ]. Limitations include restriction to a single hospital system, retrospective design, and minimal HS severity data.…”

Section: Discussionsupporting

confidence: 93%

COVID-19 Infection in Hidradenitis Suppurativa Patients: A Retrospective Study

De¹,

Rick²,

Shih³

et al. 2023

Skin Appendage Disord

View full text Add to dashboard Cite

Introduction: Hidradenitis suppurativa (HS) is associated with comorbidities that are risk factors for severe COVID-19 infection. We evaluated demographics and COVID-19 outcomes in HS patients. Methods: HS patients with COVID-19 (HS+/COVID+) and a randomized age-, race-, and sex-matched control population of patients without HS with COVID-19 (HS−/COVID+) were selected through a retrospective chart review. Data were collected on demographics, medications, comorbidities, vaccination status, and COVID-19 treatment/outcomes. Fisher’s exact test was used to analyze the relationship between risk factors and COVID-19 outcomes. A p value of <0.05 was considered statistically significant. Results: There were 58 HS+/COVID+ patients, primarily African American (83%, n = 48) and female (88%, n = 51). Compared to HS+/COVID+ patients, HS−/COVID+ patients were significantly more likely to have cardiovascular disease (51% vs. 24%; p = 0.0029) and be pregnant (23% vs. 4%; p = 0.0093). HS+/COVID+ and HS−/COVID+ patients did not vary significantly in vaccination rate at time of COVID-19 diagnosis (6% vs. 5%; p = 0.78). HS−/COVID+ patients were significantly more likely to have COVID-19 complications (35% vs. 7%; p = 0.001) and receive COVID-19 treatment (37% vs. 7%; p = 0.0001) when compared to HS+/COVID+ patients. Conclusion: Our findings support the growing evidence that having HS itself may not be a risk factor for severe COVID-19 outcomes.

show abstract

Section: Discussionsupporting

confidence: 93%

COVID-19 Infection in Hidradenitis Suppurativa Patients: A Retrospective Study

De¹,

Rick²,

Shih³

et al. 2023

Skin Appendage Disord

View full text Add to dashboard Cite

show abstract

contrasting

confidence: 46%

“…The prodrug of teriflunomide, leflunomide, is also known to be associated with the development of psoriasis. 4 Compared with the other published case reports of teriflunomideinduced pustular psoriasis, our patient developed pustular psoriasis within days rather than weeks, but otherwise the cases were similar, in that they all occurred in patients in their fifties without any personal or family history of psoriasis.This case contributes a further example of this uncommon AE of teriflunomide. As it can take 2 years for this drug to be fully eliminated from the body, it is important to be aware of psoriasis in this patient population and recognize the availability of accelerated elimination schedules to limit patient exposure to the drug if their disease is proving difficult to treat.…”

contrasting

confidence: 46%

“…Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder that causes abscesses in intertriginous areas and is known to have significant inflammatory burden that leads to systemic manifestations. 4 HS is of interest as both the disease process and common drug therapies may cause immune system dysregulation. The aim of this study was to investigate the safety and efficacy of COVID‐19 vaccines among patients with HS.…”

Section: Tablementioning

confidence: 99%

See 1 more Smart Citation

Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa

Pakhchanian

Raiker

DeYoung

et al. 2022

Clinical and Experimental Dermatology

Self Cite

View full text Add to dashboard Cite

At 6 weeks from initiation of treatment, the patient had more severe disease and development of psoriatic nail disease (Fig. 1a). He was commenced on calcipotriol ointment (Dovonex â ; LEO Laboratories) and acitretin, which brought about marked improvement in his skin. He completed 3 months of acitretin with good results, at which point the drug was discontinued. Accelerated elimination of teriflunomide was not required due to the good response to treatment.In postmarketing surveillance of teriflunomide, which was licensed in the European Union in 2013, there was evidence for a potential causal role of teriflunomide in new onset and worsening of psoriasis in patients. The prodrug of teriflunomide, leflunomide, is also known to be associated with the development of psoriasis. 4 Compared with the other published case reports of teriflunomideinduced pustular psoriasis, our patient developed pustular psoriasis within days rather than weeks, but otherwise the cases were similar, in that they all occurred in patients in their fifties without any personal or family history of psoriasis.This case contributes a further example of this uncommon AE of teriflunomide. As it can take 2 years for this drug to be fully eliminated from the body, it is important to be aware of psoriasis in this patient population and recognize the availability of accelerated elimination schedules to limit patient exposure to the drug if their disease is proving difficult to treat.

show abstract

“…Anecdotally, we have witnessed COVID-19 vaccine hesitancy and misinformation in the HS patient population. Recent studies examining COVID-19 outcomes among patients with and without HS have shown that HS patients, many of whom were on immunosuppressive and immunomodulating therapies, do not have worse outcomes than the general population [ 1 , 3 , 4 ]. Regardless of observed outcomes, vaccination remains a public health priority.…”

Section: Introductionmentioning

confidence: 99%

Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts

Rick

Shih

et al. 2022

Skin Appendage Disord

View full text Add to dashboard Cite

Introduction: Hidradenitis suppurativa (HS) patients may be at increased risk of COVID-19 infection and complications from their medications and comorbidities. There is a lack of expert consensus on recommendations for the COVID-19 vaccine for HS patients. Herein, we aim to provide expert-driven consensus recommendations regarding COVID-19 vaccinations in HS patients. Methods: A modified Delphi consensus survey developed by a core committee of 7 dermatologist HS experts consisting of 4 demographic questions and 12 practice statements was distributed to the US HS Foundation-sponsored provider listserv. Participants were attending physician HS experts. Survey results were to be reviewed by the core group and revised and resubmitted until consensus (≥70% agreement) was achieved. Results: Among the 33 survey participants, there were 30 (87%) dermatologists, 1 general surgeon, 1 plastic surgeon, and 1 rheumatologist. Consensus for all 12 statements on vaccine counseling and HS treatment counseling was achieved after the first round. Discussion/Conclusion: For now, this consensus can serve as a resource for clinicians discussing COVID-19 vaccination with their HS patients. These recommendations will need to be updated as new evidence on COVID-19 emerges.

show abstract

Coronavirus disease 2019 complications in patients with hidradenitis suppurativa: A multicenter analysis

Cited by 5 publications

References 6 publications

COVID-19 Infection in Hidradenitis Suppurativa Patients: A Retrospective Study

COVID-19 Infection in Hidradenitis Suppurativa Patients: A Retrospective Study

Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa

Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts

Contact Info

Product

Resources

About